A pharmaceutical composition for treatment of diseases associated with decrease
in bone mass comprising an EP4 agonist as an active ingredient.
An EP4 agonist, in which includes a compound possessing prostaglandin
skeleton as a representative, possesses promoting action on bone formation, so
it is useful for treatment and/or prevention of diseases associated with decrease
in bone mass.
